Axial | Jotup

Axial's 2022 Lower Middle Market Pursuits Report Highlights the Market's Stability in the Face of Volatility

Retrieved on:

Thursday, November 17, 2022

Marketing, Small business, LOI, Letter, Sales, Axial

NEW YORK, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Axial, the online M&A platform for small business acquisitions, has released its Q3 2022 Lower Middle Market Pursuits Report.

Key Points:

NEW YORK, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Axial, the online M&A platform for small business acquisitions, has released its Q3 2022 Lower Middle Market Pursuits Report.
Lower middle market buyers grew more serious in the third quarter, with LOI activity beginning to reflect the top of funnel activity witnessed in the first half of 2022.
"The first half of 2022 was characterized by lots of top-of-funnel conversation and connection between buyer and seller, but much more limited LOI and closed deal activity.
The company's pioneering deal sourcing and deal marketing platforms are trusted by professional acquirers, top lower middle market M&A advisors, and transaction-ready business owners.

Axial Therapeutics CEO A. Stewart Campbell to Present at Microbiome Connect: USA 2022

Retrieved on:

Tuesday, November 1, 2022

Autism, GLOBE, Axial, Bacteria, W. Stewart Campbell, Learning, Therapy, Irritability, Drug development, Central nervous system, Pharmaceutical industry

The event will bring together 300+ leaders from the microbiome community for three days of learning, networking and forging successful partnerships at a pivotal time for microbial drug development.

Key Points:

The event will bring together 300+ leaders from the microbiome community for three days of learning, networking and forging successful partnerships at a pivotal time for microbial drug development.
Axial Therapeutics is a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological disorders and conditions.
The company is a scientific leader in the biological role of the microbiome-gut-brain axis and its influence on the central nervous system.
Axials lead product candidate is AB-2004, a molecular therapeutic in Phase 2b clinical trials for the treatment of irritability in children with autism.

eMerge M&A Ranked #1 Lower Middle Market Investment Bank by Axial

Retrieved on:

Tuesday, November 1, 2022

Enterprise value, LOI, Standings, GLOBE, NDAS, Criterion, Intention, Lois, Gentlemen's agreement, Emerge, TEV, Financial adviser, Risk management, Axial

eMerge M&A has worked with, and sold, hundreds of private companies and completed over $5 billion in transactions.

Key Points:

eMerge M&A has worked with, and sold, hundreds of private companies and completed over $5 billion in transactions.
We get to know the owners' companies as well as they know their own companies to be most effective in the market.
Axial is the trusted deal platform serving the lower middle market ($5-$250M Total Enterprise Value (TEV)).
Closed Deals: How many deals have the advisor closed where they involved one or more Axial buyers in the process.

Former YASA CEO Chris Harris to Lead Electric Aerospace Powertrain Company Evolito as It Accelerates the Commercialisation of Electric Flight

Retrieved on:

Tuesday, November 1, 2022

Evolito Limited , a privately-owned company developing and manufacturing electric motors and powertrains for aerospace applications, has today announced former YASA CEO, Dr. Chris Harris, is joining the company as CEO.

Key Points:

Evolito Limited , a privately-owned company developing and manufacturing electric motors and powertrains for aerospace applications, has today announced former YASA CEO, Dr. Chris Harris, is joining the company as CEO.
Following 15 years experience building and leading high-tech, high-growth businesses in the UK, Europe and US, Dr. Chris Harris joined YASA in 2012.
Under Chris Harris leadership, Evolitos revolutionary electric motors and powertrains will enable electric flight to become a commercial reality in the near future.
Dr. Chris Harris, Evolito co-founder and CEO said, Electric flight requires ultra high-power density, super low-weight electric powertrains.

Axial Releases the Top 25 Lower Middle Market Investment Banks for Q3 2022

Retrieved on:

Thursday, October 20, 2022

Marketing, Hospitality, Health care, Technology, Employment, Food, Food, Hospitality and Services Union, CEO, Transport, GLOBE, EBITDA, Financial services, Recession, Final good, Corporate services, Renewable energy, Energy, Axial, Q3

NEW YORK, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Axial, the online M&A platform for buyers, advisors, and sellers of small and medium-sized businesses, has released its Q3 2022 Lower Middle Market Investment Banking League Tables.

Key Points:

NEW YORK, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Axial, the online M&A platform for buyers, advisors, and sellers of small and medium-sized businesses, has released its Q3 2022 Lower Middle Market Investment Banking League Tables.
And nowhere is this clearer than in the lower middle market, which continues to see robust deal flow despite slightly relaxed growth in Q3.
Congratulations to Q3's Top 25 lower middle market investment banks for their strong results during this period."
Investment banks took more than 680 deals to market via Axial in Q3, representing a 19.6% increase in year-over-year deal flow.

Axial Releases the 'Consumer Top 50,' Profiling the Platform's Top 50 Lower Middle Market Consumer Investors & M&A Advisors

Retrieved on:

Thursday, October 13, 2022

GLOBE, Marketing, LOI, Acquisition, Industry, Sale, Founder, CEO, Uncertainty, Mecum Dealmakers, Online shopping, Axial

NEW YORK, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Axial, the online M&A platform for buyers, advisors, and sellers of small and medium-sized businesses, has released its 2022 Lower Middle Market Consumer Top 50, profiling the platform's top 50 Lower Middle Market Consumer Investors and M&A Advisors.

Key Points:

NEW YORK, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Axial, the online M&A platform for buyers, advisors, and sellers of small and medium-sized businesses, has released its 2022 Lower Middle Market Consumer Top 50, profiling the platform's top 50 Lower Middle Market Consumer Investors and M&A Advisors.
We are now firmly in a buyer's market when it comes to consumer M&A," says Peter Lehrman, CEO and Founder of Axial.
"Inflation and interest rate hikes are playing out in consumer M&A among the retail, distribution and manufacturing companies that play in the lower middle market."
The company's pioneering deal sourcing and deal marketing platforms are trusted by professional acquirers, top lower middle market M&A advisors, and transaction-ready business owners.

Axial Therapeutics Expands Clinical Development Capabilities with Key Appointments

Retrieved on:

Tuesday, October 11, 2022

WOBURN, Mass., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for neurological conditions and oncology, today announced that it is building on its clinical development science and operations capabilities through recent key appointments. These appointments include: Gabriel Belfort, MD, PhD, Vice President, Clinical Development Sciences and Operations, Kelly Bourdon, Head of Clinical Operations, Philinia Lehr RN, MSN, Head of Clinical Trial Recruitment and Margaret Nelson-Lowe, PhD, Associate Director, Clinical Operations.

Key Points:

- Clinical development operations focused on ongoing Phase 2b clinical trial of AB-2004 in autism; data anticipated in 2023 -
WOBURN, Mass., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for neurological conditions and oncology, today announced that it is building on its clinical development science and operations capabilities through recent key appointments.
These appointments include: Gabriel Belfort, MD, PhD, Vice President, Clinical Development Sciences and Operations, Kelly Bourdon, Head of Clinical Operations, Philinia Lehr RN, MSN, Head of Clinical Trial Recruitment and Margaret Nelson-Lowe, PhD, Associate Director, Clinical Operations.
We are excited to be moving to this next stage of the companys growth with the addition of these key clinical development team members as we advance our Phase 2b clinical trial for AB-2004 to treat irritability associated with autism, said Stew Campbell, CEO of Axial Therapeutics.
Axial Therapeutics is a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological disorders and conditions.

Axial Therapeutics to Present at BioJapan Conference

Retrieved on:

Thursday, October 6, 2022

Drug discovery, Therapy, University of Tokyo, Lists of diseases, W. Stewart Campbell, University, Irritability, Autism, Bacteria, GLOBE, Axial, Central nervous system, Fine chemical, Pharmaceutical industry

To learn more about BioJapan, visit https://jcd-expo.jp/en/ .

Key Points:

To learn more about BioJapan, visit https://jcd-expo.jp/en/ .
Axial Therapeutics is a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological disorders and conditions.
The company is a scientific leader in the biological role of the microbiome-gut-brain axis and its influence on the central nervous system.
The company is advancing a pipeline of microbial-inspired therapeutics for conditions with significant unmet patient need, including autism and Parkinsons disease, and is also pursuing pre-clinical discovery of gut-targeted therapies in oncology.

Meliora Therapeutics Raises $11M Seed Financing to Develop First Mechanism Of Action Atlas in Oncology

Retrieved on:

Thursday, September 29, 2022

Founded in September 2021, Melioras computational platform enables researchers to develop a precise understanding of a drugs true mechanism of action (MOA) based on data and not guesswork.

Key Points:

Founded in September 2021, Melioras computational platform enables researchers to develop a precise understanding of a drugs true mechanism of action (MOA) based on data and not guesswork.
Out of all the areas of medicine, clinical trials in oncology have the absolute lowest success rate3%.
Meliora is using a novel molecular fingerprint matching method to determine the true mechanism of action of precision cancer therapies, said David Li, CEO & Co-Founder, Meliora Therapeutics.
"We believe AI will bring revolutionary changes to the drug discovery industry, and are impressed by Meliora's approach to develop a mechanism fingerprint atlas.

Axial Therapeutics CEO, A. Stewart Campbell, to Participate at the Longwood Healthcare Leaders Fall Webconference

Retrieved on:

Tuesday, September 13, 2022

Therapy, Central nervous system, Lists of diseases, W. Stewart Campbell, Organic, Targeted therapy, Patient, Irritability, Chief executive officer, Bacteria, Axial, GLOBE, Autism, Pharmaceutical industry

WOBURN, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Axial Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for neurological conditions and oncology, today announced that A. Stewart Campbell, Ph.D., will participate in a panel entitled The Next Wave of Targeted Therapies at the Longwood Healthcare Leaders Fall webconference on Wednesday, September 21, 2022.

Key Points:

WOBURN, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Axial Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for neurological conditions and oncology, today announced that A. Stewart Campbell, Ph.D., will participate in a panel entitled The Next Wave of Targeted Therapies at the Longwood Healthcare Leaders Fall webconference on Wednesday, September 21, 2022.
Longwood Healthcare Leaders meetings bring together leading biotech and pharma CEOs, heads of R&D, top academics, and healthcare investors for off-the-record discussions to drive transparency and collaboration in order to accelerate the translation of discoveries into medicines to help patients.
The company is a scientific leader in the biological role of the microbiome-gut-brain axis and its influence on the central nervous system.
Axials lead product candidate is AB-2004, a molecular therapeutic in Phase 2b clinical trials for the treatment of irritability in children with autism.